Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Research & Development (2021 - 2025)

Prime Medicine filings provide 5 years of Research & Development readings, the most recent being $34.7 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 1.77% to $34.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $160.6 million, a 3.44% increase, with the full-year FY2025 number at $160.6 million, up 3.44% from a year prior.
  • Research & Development hit $34.7 million in Q4 2025 for Prime Medicine, down from $44.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $52.9 million in Q4 2021 to a low of $7.4 million in Q3 2021.
  • Median Research & Development over the past 5 years was $36.2 million (2024), compared with a mean of $33.9 million.
  • The widest YoY moves for Research & Development: up 238.47% in 2022, down 45.05% in 2022.
  • Prime Medicine's Research & Development stood at $52.9 million in 2021, then tumbled by 45.05% to $29.1 million in 2022, then soared by 42.66% to $41.5 million in 2023, then fell by 17.74% to $34.1 million in 2024, then grew by 1.77% to $34.7 million in 2025.
  • The last three reported values for Research & Development were $34.7 million (Q4 2025), $44.0 million (Q3 2025), and $41.4 million (Q2 2025) per Business Quant data.